TACE联合索拉非尼与TACE联合125I粒子植入治疗肝细胞癌合并门静脉癌栓和动静脉瘘的比较

摘要/Abstract

摘要： 目的分析TACE联合索拉非尼与TACE联合¹²⁵I粒子植入治疗肝细胞癌合并门静脉癌栓和动静脉瘘的比较。方法 2019年4月—2022年4月苏州市中西医结合医院收治的肝细胞癌合并门静脉癌栓和动静脉瘘患者62例,随机均分为对照组、观察组。对照组采用TACE联合索拉非尼的治疗方法,观察组采用TACE联合¹²⁵I粒子植入治疗。结果观察组临床疗效总有效率(83.8%)高于对照组[(58.0%),P<0.05];观察组血清甲胎蛋白(AFP)、血小板(PLT)、白细胞(WBC)、红细胞(RBC)指标[(213.3±8.6)ng/mL、(154.3±8.3)×10⁹/L、(4.2±0.5)×10⁹/L、(2.0±0.3)×10¹²/L]均优于对照组[(117.5±6.8)ng/mL、(168.7±10.9)×10⁹/L、(5.7±0.7)×10⁹/L、(3.8±0.8)×10¹²/L,P<0.05];观察组天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、白蛋白(Alb)水平[(23.5±7.8)IU/L、(30.7±4.9)IU/L、(6.7±2.7)μmol/L、(39.8±2.8)g/L]均优于对照组[(35.6±12.6)IU/L、(34.3±6.3)IU/L、(13.2±2.5)μmol/L、(36.0±2.3)g/L,P<0.05];观察组发热、腹水、恶心、呕吐、感染等并发症的发生率明显低于对照组(P<0.05)。结论与TACE联合索拉非尼相比,TACE联合植入¹²⁵I粒子治疗门静脉血栓和动静脉瘘的肝癌,对肝功能的损害较小,病情改善较好,缓解症状,减少并发症的发生,值得临床使用。

关键词: 肝动脉化疗栓塞术, 索拉非尼, ¹²⁵I粒子, 肝细胞癌, 门静脉癌栓, 动静脉瘘

Abstract: Objective To compare the efficacy of TACE combined with sorafenib and TACE combined with ¹²⁵I seed implantation for the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus and arteriovenous fistula. Methods Sixty-two patients with HCC, portal vein thrombosis, and arteriovenous fistula admitted in Suzhou Hospital of Integrated Traditional Chinese and Western Medicine between April 2019 and April 2022 were enrolled in this study. The patients in the control group were treated with TACE combined with sorafenib, and the patients in the observation group was treated with TACE combined with 125I seed implantation. Results The total effective rate in the observation group (83.8%) was higher than that in the control group [(58.0%), P<0.05]; the serum levels of alpha fetoprotein (AFP), PLT, WBC, and RBC in the observation group were (213.3±8.6) ng/mL, (154.3±8.3)×10⁹/L, (4.2±0.5)×10⁹/L, (2.0±0.3)×10¹²/L, respectively. Both groups were superior to the control group [(117.5±6.8) ng/mL (168.7±10.9), respectively×10⁹/L, (5.7±0.7)×10⁹/L, (3.8±0.8)×10¹²/L, P<0.05]; the levels of AST, ALT, TBil and Alb in the observation group were (23.5±7.8) IU/L, (30.68±4.9) IU/L, (6.7±2.7) μmol/L, and (39.8±2.8) g/L, respectively, all were better than those of (35.6±12.6) IU/L, (34.3±6.3) IU/L, (13.2±2.5)μmol/L, and (36.0±2.3)g/L in the control group(P<0.05). The incidence of complications such as fever, ascites, nausea, vomiting, and infection in the observation group was significantly lower than those in the control group (P<0.05). Conclusion Compared with TACE combined with sorafenib, TACE combined with implantation of ¹²⁵I particles for treating HCC patients with portal vein thrombosis and arteriovenous fistula has less impact on liver function, with a better improvement in the treatment effect, relief of symptoms and reduction of complications, which is worthy of clinical use.

Key words: Hepatic artery chemoembolization, Sorafenib, ¹²⁵I particles, Hepatocellular carcinoma, Portal vein cancer thrombus, Arteriovenous fistula

秦锶伟, 朱晓强, 许磊磊, 骆馨. TACE联合索拉非尼与TACE联合¹²⁵I粒子植入治疗肝细胞癌合并门静脉癌栓和动静脉瘘的比较[J]. 肝脏, 2024, 29(9): 1052-1055.

QIN Si-wei, ZHU Xiao-qiang, XU Lei-lei, LUO Xin. A comparison between TACE combined with sorafenib or ¹²⁵I seed implantation for the treatment of hepatocellular carcinoma patients with portal vein tumor thrombus and arteriovenous fistula[J]. Chinese Hepatolgy, 2024, 29(9): 1052-1055.

/ 推荐

参考文献

[1] 张学文, 戴朝六. 肝细胞癌合并门静脉癌栓治疗现状与展望[J]. 临床肝胆病杂志,2019,35(4): 899-904.
[2] Tao ZW, Cheng BQ, Zhou T, et al. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review[J]. Hepatobiliary Pancreat Dis Int,2022,21(2):134-144.
[3] Khan AR, Wei X, Xu X. Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides[J]. J Hepatocell Carcinoma,2021,8:1089-1115.
[4] Shao L, Wang X, Yu Y, et al. Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer[J]. Transl Cancer Res,2021,10(8):3739-3747.
[5] Matsuda N, Imai N, Kuzuya T, et al. Progression after molecular targeted agents: hepatic arterial changes and transarterial chemoembolization in hepatocellular carcinoma[J]. In Vivo, 2021,35(2):1185-1189.
[6] 中国医师协会肝癌专业委员会, 程树群, 陈敏山, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 中华医学杂志,2019,99(8):579-586.
[7] 徐林芳, 沈曼茹, 史先芳, 等.肝硬化Child-Pugh分级与门静脉系统血流动力学指标的相关性[J]. 肝脏,2018,23(9): 791-793.
[8] Kuang J, Wan D, Wan P, et al. Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma[J]. J BUON,2021,26(3):868-874.
[9] Li D, Pang Y, Xu L, et al. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: a meta-analysis[J]. J BUON,2021,26(4):1355-1364.
[10] Xu X, Meng Q. Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma[J]. Pak J Pharm Sci,2018,31(4):1751-1755.
[11] 韦伟, 关利君. TACE联合微波消融与联合¹²⁵I放射性粒子植入治疗不可切除肝癌合并门静脉癌栓疗效比较[J].介入放射学杂志,2022,31(9): 889-893.
[12] Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study[J]. Cancer,2021,127(20):3782-3793.
[13] Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (launch)[J]. J Clin Oncol,2023,41(1):117-127.
[14] Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies[J]. Semin Liver Dis,2018,38(3):242-251.
[15] Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Radiology,2022,303(2):455-464.
[16] Qiu G, Xie K, Jin Z, et al. The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus[J]. Biosci Trends,2021,15(3):148-154.

TACE联合索拉非尼与TACE联合¹²⁵I粒子植入治疗肝细胞癌合并门静脉癌栓和动静脉瘘的比较

A comparison between TACE combined with sorafenib or ¹²⁵I seed implantation for the treatment of hepatocellular carcinoma patients with portal vein tumor thrombus and arteriovenous fistula

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈元莉, 曾德锋, 范会文. 超声造影联合超声弹性成像对肝细胞癌微血管侵犯的预测价值[J]. 肝脏, 2024, 29(9): 1035-1039.
[2]	朱继兰, 赵霞, 王市伟, 杨蕾. 多参数磁共振成像联合CT动态增强对晚期肝细胞癌免疫治疗疗效的预测价值[J]. 肝脏, 2024, 29(9): 1040-1046.
[3]	杨紫郡, 杨佳欣, 郭莉莉. DCE-MRI联合CT增强扫描在肝细胞癌TACE治疗效果评估中的价值[J]. 肝脏, 2024, 29(9): 1060-1063.
[4]	王国峰, 贾玉清, 束长新, 蔡晓东, 王洪勃, 徐件红. 不同入路下行开腹解剖性肝脏切除术治疗肝细胞癌的临床对比[J]. 肝脏, 2024, 29(9): 1064-1067.
[5]	朱洪江, 王连峰. 免疫治疗肝肉瘤样癌1例[J]. 肝脏, 2024, 29(9): 1160-1161.
[6]	柏玲, 殷慧康, 葛琦, 耿承军. MRI联合应用DWI和DCE扫描序列对HBV相关肝细胞癌功能状态的评估价值[J]. 肝脏, 2024, 29(8): 952-955.
[7]	田昳程, 唐祖雄, 汝干, 王奇, 翟春涛. HBV相关肝细胞癌患者PPP2R3A基因的表达与预后相关性分析[J]. 肝脏, 2024, 29(8): 956-959.
[8]	靖长友, 朱桐, 张永宏, 李建军. 经肝动脉化疗栓塞联合射频消融治疗早期肝癌的效果[J]. 肝脏, 2024, 29(7): 777-801.
[9]	钱叶强, 高路, 余春来. 酪氨酸激酶抑制剂联合肝动脉化疗栓塞治疗肝细胞癌的近远期疗效[J]. 肝脏, 2024, 29(7): 780-783.
[10]	张云江, 梁亮, 张东成. 卡瑞利珠单抗联合索拉非尼治疗中晚期肝细胞癌患者甲胎蛋白应答变化及对预后的评价[J]. 肝脏, 2024, 29(7): 784-787.
[11]	于健, 董文健, 夏建新, 彭仁聪. 60例不典型肝血管瘤患者声速匹配技术及剪切波弹性成像表现及其与肝细胞癌的鉴别[J]. 肝脏, 2024, 29(7): 798-801.
[12]	傅鹏, 唐亚丹, 杨方方, 杨立新. 乙型肝炎肝硬化不同性质结节在超声造影灌注时相的增强表现特点[J]. 肝脏, 2024, 29(7): 813-816.
[13]	丁一桁, 贾婧轩, 齐锦生, 栗彦宁, 郑丽. 调控HNF4α诱导肝细胞癌分化的机制进展[J]. 肝脏, 2024, 29(7): 874-877.
[14]	温浩喻, 肖潇, 马雄. 自身免疫性肝炎相关肝细胞癌流行病学及危险因素[J]. 肝脏, 2024, 29(6): 625-628.
[15]	陈杰, 许超丽, 刘洪. 肝癌术后复发患者再次肝切除、局部消融治疗的临床疗效及其预后影响因素[J]. 肝脏, 2024, 29(6): 648-651.